Loading bill breakdown…
H.R. 1266119th CongressCrime and Law Enforcement
Combating Illicit Xylazine Act
Sponsored by Rep. Jimmy Panetta (D-CA) · 114 active : 63 Republicans, 51 Democrats
Latest action: Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.
Where it standsPassed House, now in the Senate7 senators score as swing votes
Passed House
- House: passedSep 15, 2026
- Senate: next
- President: not yet
Summary
, via Congress.govCombating Illicit Xylazine Act
This bill regulates xylazine under the Controlled Substances Act (CSA).
Xylazine, also known as
tranq
, is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine.
Read full summaryHide full summary
This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused.
Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA.
The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs.
The bill also exempts xylazine manufacturers from the CSA's physical security requirements.
Finally, the bill requires the DEA, in coordination with the Food and Drug Administration, to report on (1) the prevalence and impact of illicit xylazine use in the United States, and (2) updated information on the prevalence and proliferation of xylazine trafficking and misuse in the United States.
Committees and subjects
Committees
- House Committee on Energy and Commerce · HouseReported by · Markup by · Referred to
- Health · HouseReported by · Markup by · Referred to
- House Committee on the Judiciary · HouseDischarged from · Referred to
Subjects
- Congressional oversight
- Consumer affairs
- Criminal procedure and sentencing
- Drug safety, medical device, and laboratory regulation
- Drug trafficking and controlled substances
- Licensing and registrations
- Manufacturing
- U.S. Sentencing Commission
- Veterinary medicine and animal diseases
Model
Directional: count only breaks toward the other partyWhy do scores change?v3default (selected)v2 model swing-v2
How the Senate breaks down
- 7Swing 70–100
- 66Middle 30–70
- 27Entrenched 0–30
Members fall into . All 100 senators have enough data to score.
Key players in the Senate
Ranked by swing score, 0–100 · swing-v3Bars show each input from 0 to 100: ideology gap, scorecard gap, , and the . is the seat’s partisan lean, and shows how much of the input data a score has.
Similar past votes, Senate
Earlier behind swing-v3’s inputLoading similar votes
Cosponsors
114 activeShow all 114 cosponsors
- Angie Craig (D-MN-2)
- August Pfluger (R-TX-11)
- Brian K. Fitzpatrick (R-PA-1)
- Brittany Pettersen (D-CO-7)
- Chris Pappas (D-NH-1)
- Christopher R. Deluzio (D-PA-17)
- Claudia Tenney (R-NY-24)
- Dan Crenshaw (R-TX-2)
- Daniel Webster (R-FL-11)
- Deborah K. Ross (D-NC-2)
- Diana Harshbarger (R-TN-1)
- Don Bacon (R-NE-2)
- Donald G. Davis (D-NC-1)
- Donald Norcross (D-NJ-1)
- Gus M. Bilirakis (R-FL-12)
- J. Luis Correa (D-CA-46)
- Jay Obernolte (R-CA-23)
- Jim Costa (D-CA-21)
- Josh Harder (D-CA-9)
- Juan Ciscomani (R-AZ-6)
- Madeleine Dean (D-PA-4)
- Mariannette Miller-Meeks
How the swing score works
Ideology gapHow far a member’s DW-NOMINATE voting score sits from their party’s median in the same chamber.
Scorecard gapHow far their Heritage Action and LCV ratings stray from their party’s average, using the groups’ votes on similar bills where available.
Cross-pressureHow strongly their district or state leans toward the other party, from our own computed partisan lean.
Similar votesHow often they voted against their own party on earlier roll calls about this bill or similar ones.
Committee bonusMembers of the committees handling the bill decide whether it moves, so they get a boost.
Cosponsor checkThe sponsor and active cosponsors have already committed, so they drop toward entrenched.
